TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives $6.00 Consensus Target Price from Brokerages

TScan Therapeutics, Inc. (NASDAQ:TCRX) has been given a consensus recommendation of “Hold” by the six analysts that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating on the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $6.00.

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research note on Friday. Needham & Company LLC reissued a “buy” rating and set a $6.00 price target on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Wall Street Zen downgraded shares of TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Finally, Wedbush reissued an “outperform” rating and set a $5.00 target price on shares of TScan Therapeutics in a research report on Tuesday, June 23rd.

Institutional Trading of TScan Therapeutics

A number of institutional investors have recently made changes to their positions in TCRX. Boothbay Fund Management LLC increased its position in TScan Therapeutics by 50.0% during the 2nd quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after buying an additional 8,121 shares in the last quarter. Panagora Asset Management Inc. purchased a new position in shares of TScan Therapeutics in the 4th quarter valued at approximately $25,000. HRT Financial LP acquired a new stake in TScan Therapeutics in the 4th quarter worth approximately $26,000. Public Employees Retirement System of Ohio purchased a new stake in TScan Therapeutics during the 1st quarter worth approximately $28,000. Finally, Voleon Capital Management LP acquired a new position in TScan Therapeutics during the 3rd quarter valued at approximately $87,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Price Performance

NASDAQ TCRX opened at $0.94 on Friday. The company has a market cap of $61.46 million, a PE ratio of -0.98 and a beta of 1.04. The firm’s 50 day moving average price is $0.99 and its 200-day moving average price is $1.06. The company has a debt-to-equity ratio of 0.34, a quick ratio of 6.65 and a current ratio of 6.65. TScan Therapeutics has a 52-week low of $0.83 and a 52-week high of $2.57.

TScan Therapeutics (NASDAQ:TCRX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.22). TScan Therapeutics had a negative return on equity of 91.94% and a negative net margin of 1,360.61%.The company had revenue of $0.98 million during the quarter, compared to analyst estimates of $2.50 million. Sell-side analysts forecast that TScan Therapeutics will post -1.11 EPS for the current fiscal year.

About TScan Therapeutics

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.